SUNRISE: A Phase III, Randomized, Double-Blind, Placebo-Controlled Multicenter Trial of Bavituximab Plus Docetaxel Versus Docetaxel Alone in Patients With Previously Treated Stage IIIb/IV Non-Squamous Non Small-Cell Lung Cancer
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Bavituximab (Primary) ; Docetaxel
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms SUNRISE
- Sponsors Peregrine Pharmaceuticals
- 14 May 2018 Results evaluating efficacy published in the Annals of Oncology
- 18 Oct 2017 Results of a subgroup analysis assessing outcomes in all patients who received subsequent Immune Checkpoint Inhibitors after discontinuing the study drug (n=93) presented at the 18th World Conference on Lung Cancer
- 12 Sep 2017 Results of exploratory analysis asssessing bavituximab + docetaxel versus docetaxel monotherapy, as second-line treatment, in patients with non-squamous cell advanced or metastatic non-small cell lung cancer who have progressed after standard first-line therapy, were presented at the 42nd European Society for Medical Oncology Congress.